GREENSBORO – Qorvo Biotechnologies has landed another contract – this one worth more than $4 million – from the National Institutes of Health to continue development of its diagnostic test platform which could be used for COVID-related testing.

The company is a subsidiary of Qorvo (Nasdaq: ORVO), a semiconductor and radio frequency product company.

The biotech group landed a $24.4 million contract last year to support development of its Qorvo Omnia platform. The new funding will be used for further clinical trials and market launch of two tests:

  • SARS-CoV-2/ Flu Combo Assay
  • SARS-CoV-2 Antigen Pooling

The SARS-CoV-2/Flu Combo Assay will simultaneously detect and differentiate between SARS-CoV-2, Flu A and Flu B in an all-in-one test using a single swab sample in approximately 20 minutes, according to the company.

The antigen pooling application will allow up to six samples to be processed together and tested at the same time, Qorvo Biotechnologies added.

Qorvo Biotechnologies granted emergency use authorization, awarded $24.4M contract, to produce COVID-19 rapid test

“Today’s COVID testing market is demanding high quality testing infrastructure at the point of care (POC), with automated workflow, menu expansion and scalability to serve future needs of the pandemic,” Philip Chesley, president of Qorvo Biotechnologies, said in a statement on Monday. “This contract award and continued RADx support enable Qorvo to more effectively address the expanding requirements of diverse end use settings.”